Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Headache and migraine

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).

Fabrizio Vernieri; Claudia Altamura; Nicoletta Brunelli; Carmelina Maria Costa; Cinzia Aurilia; Gabriella Egeo; Luisa Fofi; Valentina Favoni; Giulia Pierangeli; Carlo Lovati; Marco Aguggia; Florindo d'Onofrio; Alberto Doretti; Paola Di Fiore; Cinzia Finocchi; Renata Rao; Francesco Bono; Angelo Ranieri; Maria Albanese; Sabina Cevoli; Piero Barbanti; GARLIT Study Group

Originally published in The journal of headache and pain · 2021-05-03

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background The clinical benefit of galcanezumab, demonstrated in randomized clinical trials (RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) and chronic migraine (CM) in a real-life setting. Methods This multicenter prospective observational cohort study was conducted between November 2019 and January 2021 at 13 Italian headache centers. Consecutive adult HFEM and CM patients clinically eligible were enrolled and treated with galcanezumab subcutaneous injection 120 mg monthly with the first loading dose of 240 mg. The primary endpoint was the change in monthly migraine days (MMDs) in HFEM and monthly headache days (MHDs) in CM patients after 6 months of therapy (V6). Secondary endpoints were the Numerical Rating Scale (NRS), monthly painkiller intake (MPI), HIT-6 and MIDAS scores changes, ≥50% responder rates (RR), the conversion rate from CM to episodic migraine (EM) and Medication Overuse (MO) discontinuation. Results One hundred sixty-three patients (80.5% female, 47.1 ± 11.7 years, 79.8% CM) were included.

Methods

GARLIT is an independent, multicenter, prospective, cohort, real-life study ongoing at 13 Italian headache centers across seven regions from November 2019, with the latest data survey on January 31, 2021.

Results

To date, 245 patients have been enrolled in the GARLIT study. Of these 165 patients completed 6 months of observation since the first galcanezumab injections. For the current analysis, two subjects were excluded since the complete data set regarding primary studied variables were not available. We finally enrolled 163 patients (80.5% female, aged 47.1 ± 11.7 yrs., min-max 18–80 yrs). Of these, 10 patients (6.1%) dropped out for lack of effectiveness at least after 3 months of therapy, were included in the analysis as non-responders, and considered for the other endpoints for the treatment period.

Discussion

Our 6-month study demonstrated that galcanezumab appears effective, safe, and well tolerated to prevent migraine in CM and HFEM patients also in real life. We found that the MHD and MMD reductions were more extensive than those observed in the three RCTs. MMDs variation (i.e., − 8 days) was almost double in the EM group compared to the EVOLVE studies (i.e. -4.7 and − 4.3), and more than twice (i.e. -13) in the CM group versus the REGAIN (− 4.8) at 3 months.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?